...
CRNXMID

Crinetics Pharmaceuticals, Inc.

HealthcareBiotechnology
$41.10
$0.02(-6.04%)
52W$24.10
$57.99
FinancialsValuationvs AGIO
Updated Mar 2, 12:00 AM
RSI39
RS Rating61/99
Beta1.05
Volatility59%
F-Score2/9
Mkt Cap$3.9B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Crinetics Pharmaceuticals, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is moderate (RS Rating: 61), indicating performance broadly in line with the market. Earnings contraction of 48% provides fundamental context to the price action. Investors should exercise caution due to high volatility (59% annualized), which requires wider risk management.

Relative Strength
61
out of 99
Average
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
1.05
vs S&P 500
MARKET
52W Position
50%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$48.82
50 SMA > 100 SMA$46.49
100 SMA > 150 SMA$42.03
150 SMA > 200 SMA$39.27

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$45.24-9.15%BELOW
50 SMA$48.82-15.82%BELOW
100 SMA$46.49-11.60%BELOW
150 SMA$42.03-2.21%BELOW
200 SMA$39.27+4.67%ABOVE

Price Performance

1D-6.0%
1W-6.1%
1M-19.9%
3M-9.8%
6M+34.1%
YTD-12.0%
1Y+14.9%
3Y+27.9%
52-Week Trading Range50% from low
$41.10
52W Low$24.10
52W High$57.99

Technical Indicators

RSI (14)BEARISH
39.0
305070
VCP ScoreCOOL
4/10
Base depth: 42.9%

Risk Profile

Beta
1.05
52W Vol
59%
ATR
$2.31
Max DD (1Y)
-29%

Volume Analysis

Today
41
50D Avg
1.08M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q1'25-12%
$-1.04
Q2'25-31%
$-1.23
Q3'25-44%
$-1.38
Q4'25-48%
$-1.30
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+137.98%
3 Years:+4.59%
TTM:+421.66%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-33.42%

Stock Price CAGR

10 Years:+5.31%
5 Years:+21.24%
3 Years:+27.91%
1 Year:+14.87%

Return on Equity

10Y Avg:-57.4%
5Y Avg:-43.2%
3Y Avg:-40.8%
Last Year:-46.9%

Key Metrics

Market Cap$3.9B
Gross Margin80.1%
Net Margin-85.9%
Piotroski F-Score2/9

More CRNX Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

CRNX vs AGIOAGIOVRTXASNDBBIO

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 61 meansCRNX outperformed 61% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.05 means 5% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 2/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is CRNX in an uptrend right now?

CRNX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is CRNX overbought or oversold?

CRNX's RSI (14) is 39. The stock is in neutral territory, neither overbought nor oversold.

Is CRNX outperforming the market?

CRNX has a Relative Strength (RS) Rating of 61 out of 99. CRNX is performing about average compared to the market.

Where is CRNX in its 52-week range?

CRNX is trading at $41.10, which is 71% of its 52-week high ($57.99) and 50% above its 52-week low ($24.10).

How volatile is CRNX?

CRNX has a Beta of 1.05 and 52-week volatility of 59%. It's more volatile than the S&P 500 - expect bigger swings.